In 2026, a pre-revenue digital therapeutics startup often finds itself in a bind: payers, clinicians, and investors...
DTx evidence
As digital therapeutics (DTx) expand into chronic disease management, the pressure to generate compelling evidence for payer...
The phrase synthetic control arms in regulatory filings once belonged to statistically minded insiders discussing methodological curiosities....
The large, placebo-controlled trial is no longer the default for digital therapeutics. As DTx evidence generation enters...